Abstract: Substituted heterocyclic derivatives are provided which have the structure wherein Z1 is (CH2)q or C?O; Z2 is (CH2)p or C?O; D is —CH? or C?O or (CH2)m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N, O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4, X5 and X6 is N; and at least one of X2, X3, X4, X5 and X6 is C; A, B, R1, R2, R2a, R2b, R4, R3, E, Z and Y are as defined herein. In addition, a method is provided for treating diabetes, Type 2 diabetes, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, or atherosclerosis, wherein the substituted heterocyclic derivatives are administered in a therapeutically effective amount to a patient.

Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R6, R7, and R8 are defined herein.

Abstract: Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmeutical formulations thereof.

Abstract: A method of treating a patient suffering a disease associated with Trichophyton mentagrophytes or Pityrosporum ovale by applying topically an anti-fungal pharmaceutical composition which is prepared from Zingiber officinale, includes the following steps: preparing a crude liquid from rhizomes of ginger by extraction with an organic solvent or supercritical CO2, or by distillation with steam; introducing the crude liquid to a reverse phase chromatography column, and eluting the column with water, a first eluent and a second eluent having a polarity weaker than that of the first eluent but stronger than that of chloroform, so that a first eluate resulting from elution of the first eluent and a second eluate resulting from elution of the second eluent are obtained; removing the first eluent and the second eluent from the first eluate and the second eluate by evaporation, respectively, so that a first concentrated eluate and a second concentrated eluate are obtained as the potent extract.

Abstract: Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

Abstract: 1

Abstract: A method of preparing an extract which is potent in anti-fungal activity from Zingiber officinale, includes the following steps: preparing a crude liquid from rhizomes of ginger by extraction with an organic solvent or supercritical CO2, or by distillation with steam; introducing the crude liquid to a reverse phase chromatography column, and eluting the column with water, a first eluent and a second eluent having a polarity weaker than that of the first eluent but stronger than that of chloroform, so that a first eluate resulting from elution of the first eluent and a second eluate resulting from elution of the second eluent are obtained; removing the first eluent and the second eluent from the first eluate and the second eluate by evaporation, respectively, so that a first concentrated eluate and a second concentrated eluate are obtained as the potent extract.

Abstract: A rotational balancing structure for an A.C. motor comprises a casing having an axle seat for rotatably holding a shaft of a rotor. A balancing sheet and a stator are mounted in the casing. The stator comprises plural stacked silicon steel plate wound around by a winding. An insulating ring is mounted to an end of the stator. Each of the stator and the insulating ring has a central hole. The rotor comprises an induction ring that is received in the central hole of the stator with an end face of the induction ring extending through the central hole of the stator for mutual attraction with the balancing sheet fixed on the casing.

Abstract: A method of preparing an extract which is potent in anti-fungal activity from Zingiber officinale, includes the following steps: preparing a crude liquid from rhizomes of ginger by extraction with an organic solvent or supercritical CO2, or by distillation with steam; introducing the crude liquid to a reverse phase chromatography column, and eluting the column with water, a first eluent and a second eluent having a polarity weaker than that of the first eluent but stronger than that of chloroform, so that a first eluate resulting from elution of the first eluent and a second eluate resulting from elution of the second eluent are obtained; removing the first eluent and the second eluent from the first eluate and the second eluate by evaporation, respectively, so that a first concentrated eluate and a second concentrated eluate are obtained as the potent extract.

Abstract: This invention is directed to benzenamine derivatives of formula (I): wherein A, W, m, n, R1, R2, R3, R4, R5 and R6 are defined herein. These compounds are useful as anti-coagulants.

Abstract: A method of preparing an extract from Zingiber officinale, which is potent in anti-inflammation and anti-platelet aggregation, includes the following steps: a) preparing a crude liquid from rhizomes of ginger by extraction with an organic solvent or by distillation with steam; b) introducing the crude liquid to a reverse phase chromatography column, and eluting the column with water, a first eluent and a second eluent having a polarity weaker than that of the first eluent but stronger than that of chloroform, so that a first eluate resulting from elution of the first eluent and a second eluate resulting from elution of the second eluent are obtained; c) removing the first eluent from the first eluate by evaporation, so that a first concentrated eluate is obtained and is able to used as the potent extract; and d) removing the second eluent from the second eluate by evaporation, so that a second concentrated eluate is obtained and is able to used as the potent extract.

Abstract: A pharmaceutical composition which possesses vasorelaxing effect of aortic contraction, relaxing effect of tracheal contraction, and antioxidative properties, is disclosed. It contains a pharmaceutical acceptable vehicle and an effective amount of any compound selected from those compounds represented by the following formula: ##STR1## where R.sub.1 represents H, C.sub.1-8 alkyl, or --OCOR, R.sub.2 represents OH, or COO.sup.--, and R represents H, or C.sub.1-8 alkyl.

Abstract: The present invention discloses the method of isolation and purification of the bioactive constituents cinnamophilin from Cinnamomum philippinense (Merr.), the same as Machilus acuminatissima (Hayata). Pharmacological evaluation showed that these compounds possess the activity to inhibit platelet aggregation and to produce relaxing effects of aortic vascular constriction.

Abstract: A method of inhibiting tumor-cell growth in a mammalian subject, by administering a therapeutically effective amount of a selected 2-phenyl-4-quinolone compound. The selected compound shows unexpectely high activity against a variety of solid tumor cells.

Abstract: The subject invention discloses methods of inhibiting growth of tumor cells which comprise contacting the cells with a growth inhibiting amount of a compound having one of following structures: ##STR1## wherein R.sup.1 is a hydroxyl or acetyl group; R.sup.2 is hydrogen, --CH.sub.2 --CH.dbd.C(CH.sub.3).sub.2 or a method group; R.sup.3 is a hydroxyl, methoxy or acetyl group; R.sup.4 is hydrogen, --CH.sub.2 --CH.dbd.C(CH.sub.3).sub.2 or a methoxy group; R.sup.5 is a hydroxyl, methoxy or acetyl group; is hydrogen or a hydroxyl, methoxy or acetyl group; and R.sup.10 is a methyl group, ##STR2## wherein R.sup.5 is hydrogen or --CH.sub.2 --CH.dbd.C(CH.sub.3).sub.2 ; R.sup.6 is a hydroxyl group; R.sup.10 is hydrogen or a hydroxyl group; R.sup.11 is a hydroxyl or methoxy group; and R.sup.12 is hydrogen or a methyl group.